AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer’s Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer’s Disease and Intermediate Amyloid (A3 Trial)


Total Award Amount

  • 1596543.00
  • Direct Costs

  • 1228110.00
  • Sponsor Award Id

  • Contributor

  • Bryan Smelser   Investigator  
  • David Geldmacher   Investigator  
  • Marissa Natelson Love   Principal Investigator  
  • Roberta May   Investigator